MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
DiaMedica Therapeutics Cash Conversion Cycle 2011-2026 | DMAC
Quarterly Cash Conversion Cycle DiaMedica Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 142 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 142 | 142 | 142 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Xeris Pharmaceuticals
XERS
|
535 | $ 6.03 | -1.55 % | $ 885 M |  USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
UroGen Pharma Ltd.
URGN
|
127 | $ 19.2 | -11.52 % | $ 554 M |  Israel |
 |
uniQure N.V.
QURE
|
-1.34 K | $ 10.89 | -30.36 % | $ 530 M |  Niderland |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 3.74 | 3.6 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-8.96 K | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-6 K | $ 3.36 | 0.86 % | $ 1.2 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M | Israel |
 |
Agios Pharmaceuticals
AGIO
|
735 | $ 29.16 | -3.54 % | $ 1.69 B | USA |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Завод ДИОД
DIOD
|
-32.7 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
-15.9 | - | - | - | Russia |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Alector
ALEC
|
-13.8 | $ 2.19 | -9.77 % | $ 226 M | USA |
 |
Altimmune
ALT
|
15.1 K | $ 4.21 | -2.32 % | $ 299 M | USA |
 |
Teligent, Inc.
TLGT
|
120 | - | -13.85 % | $ 16.1 M | USA |
 |
Evogene Ltd.
EVGN
|
-32.5 | $ 0.84 | -4.24 % | $ 27.9 M | Israel |
 |
Viela Bio, Inc.
VIE
|
139 | - | - | $ 2.91 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
213 | $ 13.98 | 1.27 % | $ 5.7 B |  Irlanda |
 |
AbbVie
ABBV
|
284 | $ 233.57 | 0.64 % | $ 413 B | USA |
 |
Blueprint Medicines Corporation
BPMC
|
254 | - | - | $ 8.14 B | USA |
 |
AIM ImmunoTech
AIM
|
46 | $ 0.8 | -11.6 % | $ 38.5 M | USA |
 |
Aptorum Group Limited
APM
|
-400 | $ 0.83 | 5.37 % | $ 4.53 M | China |
 |
Apellis Pharmaceuticals
APLS
|
115 | $ 20.67 | -1.38 % | $ 2.61 B | USA |